Rapid Response to the Combination of Lenvatinib and Sintilimab in a Pancreatic Acinar Cell Carcinoma Patient With Elevated Alpha-Fetoprotein: A Case Report

Lanqun Qin1†, Jie Shen1,2,3†, Yueling Yang3 and Zhengyun Zou1,2,3,*

1 The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, China, 2 The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China, 3 The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, Nanjing, China

A 48-year old woman was diagnosed with metastatic pancreatic acinar cell carcinoma (PACC) and with a marked elevation in alpha-fetoprotein (AFP), this being a recognized but uncommon feature of PACC. As she refused chemotherapy, the combined therapy of lenvatinib and sintilimab (lenvatinib 8 mg, orally, qd; and sintilimab 100 mg, intravenous glucose tolerance test, q21d) was given, which conferred significant tumor shrinkage and long progression-free survival (>21 months). This study is the first report and description of a PACC demonstrating favorable response to the combination therapy of an antiangiogenic agent and immunotherapy.

Keywords: alpha-fetoprotein, sintilimab, lenvatinib, pancreatic acinar cell carcinoma, case report

INTRODUCTION

Acinar cell carcinoma (ACC) is an epithelial tumor similar to the acinar cells of the exocrine gland (1). It can originate from the pancreas, salivary gland, prostate, and lung (2), among which pancreatic acinar cell carcinoma (PACC) is the most common. PACC, which was first reported in 1908, accounts for 1%–2% of all pancreatic tumors and mainly occurs in the pancreas head of medium-elderly men (3, 4). However, alpha-fetoprotein (AFP)-elevated PACC is rare with no more than 30 cases being reported worldwide (5, 6).

Since PACC is generally asymptomatic in the early stages, clinical presentation is often delayed, and about 50% of cases already have metastatic disease at diagnosis. The liver is the most commonly affected site (7). There are no specific tumor indicators, but elevated AFP has been reported (7, 8), which can level up to >160,780 ng/ml (9). This may be related to the fact that AFP is a secreted product of liver cancer cells.
CASE PRESENTATION

A 48-year-old female underwent right total hip replacement because of right hip trauma on December 4, 2019. Pathological findings showed that local tissue of the femoral head was necrotic with a heterogeneous epithelial infiltration between the trabeculae, consistent with a metastatic adenocarcinoma (Figure 1). Immunohistochemistry was negative for markers CD7, CK20, TTF1, PAX8, S100, HMB45, Hept1, GATA3, SALL4, HCG, GPC3, or NY-ESO-1 but positive for CK and Villin. However, the primary tumor still remained unclear, as she refused liver biopsy. Abdominal MRI showed multiple occupations in the liver and around the pancreatic tail (Figure 2), while gynecological B-ultrasound and

![Figure 1](image1.png)

**FIGURE 1** | Pathology after hip replacement (H&E staining) showed heterogeneous epithelial cell infiltrating between trabeculae. The left was taken at ×20, and the right was taken at ×10.

![Figure 2](image2.png)

**FIGURE 2** | The baseline laboratory and imaging examinations for the patient. (A, B) Magnetic resonance imaging (MRI) of the upper abdomen. Tumor lesions are marked by red arrows. (C) Laboratory data on admission (outliers are highlighted in red). WBC, white blood cell count; N, neutrophil count; RBC, red blood cell count; Hb, hemoglobin; PLT, blood platelet count; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; CA125, carbohydrate antigen 125; CA199, carbohydrate antigen 19-9; CA724, carbohydrate antigen 724; CA242, carbohydrate antigen 242; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; T-Bil, total bilirubin; D-Bil, direct bilirubin; CHE, cholinesterase; TP, total protein; Alb, albumin; BUN, blood urea nitrogen; Cre, creatinine; Na, sodium; K, potassium; Cl, chloride; CRP, C-reactive protein; eGFR, glomerular filtration rate; HBsAg, hepatitis B surface antigen; HBsAb, hepatitis B surface antibody; HBeAg, hepatitis B e antigen; HBeAb, hepatitis B e antibody; HBCAg, hepatitis B core antigen; HBcAb, hepatitis B core antibody; HCV-Ag, hepatitis C virus antigen; HCV-Ab, hepatitis C virus antibody; PT, prothrombin time; INR, international normalized ratio; APTT, activated partial thromboplastin time; TT, thrombin time.
gastroenteroscopy revealed no abnormality. The patient had no history of hepatitis but had diabetes.

Despite the elevated AFP, the lack of rapid filling and rapid washout of contrast in the liver lesions in CT and absence of antecedents such as hepatitis or alcohol consumption goes against the liver lesions being hepatocellular carcinoma (HCC). After multidisciplinary discussion and literature retrieval, the patient was eventually diagnosed with PACC clinically based on her radiographic data: large diameter, common internal necrosis, exophytic growth, and a well-defined margin with enhanced capsule, often invading peripheral blood vessels, which are the typical radiographic features of PACC (10).

There is no standard treatment for PACC due to its rarity, and the patient refused chemotherapy for fear of chemotherapy-related side effects. Abdominal CT showed multiple masses in the liver and a solitary 3.7-cm mass in the pancreatic tail with a rich blood supply to the tumor, which is the key point to choose antiangiogenic agents. And through literature review, we also found synergy effects of antiangiogenic agents combined with anti-PD-1 antibody. After discussion, the patient consented to undergo a combination therapy of sintilimab (a multitargeted tyrosine kinase inhibitor (TKI)) and lenvatinib (an analog of pembrolizumab with a much lower cost). Three weeks into the treatment, her AFP levels (Figure 3A) dropped dramatically, and tumor lesions (Figure 3B) shrank significantly. The patient has demonstrated a partial response (PR) of 21 months since the start of treatment. No severe grade 3 and beyond side effects were observed.

**DISCUSSION**

Due to its rarity, there is no standard treatment for PACC. Complete resection is always the preferred option (11), and chemotherapy often refers to the regimens of colorectal cancer or ductal adenocarcinoma based on their similar genetic changes.

**FIGURE 3** | The comparison of tumor indicators and CT images. (A) A timeline outlining the treatment course (lenvatinib 8 mg, orally, qd; and sintilimab 100 mg, intravenous glucose tolerance test, q21d) and changes of laboratory indicators including alpha-fetoprotein (AFP), neutrophils, lactate dehydrogenase (LDH), and eosinophils. (B) Imaging changes of the first four times of evaluation with tumor lesions marked by red arrows.
for those who cannot undergo resection (12). A retrospective study showed that about 50%–60% patients diagnosed with metastatic PACC responded to a possible combination of gemcitabine, docetaxel, and erlotinib (13). Antoine et al. also reported a PACC case with liver metastasis who survived for 37 months through a combined therapy with gemcitabine, irinotecan, docetaxel, etc (14). Some studies evaluated the chemical sensitivity of drugs by ATP-CRA and found that cyclophosphamide is the most ideal drug for AFP-producing PACC (15).

The combination therapy of antiangiogenic agents and immunotherapy has shown certain efficacy in a variety of tumors, such as renal cell carcinoma (16, 17), HCC (18), and malignant melanoma (19). Recently, this combination also showed a strong therapeutic effect for a tumor mutational burden (TMB)-high pancreatic cancer patient after a series of ineffective treatments (20). Unfortunately, the patient refused to undergo liver biopsy, so no specimen was available for further analysis of mismatch repair deficient (dMMR), PD-L1, TMB, and other immune-related markers.

The liver is an organ with high vascularization and immunogenicity, and liver metastasis often suggests poor prognosis. Lenvatinib, a multitargeted TKI, definitely had a certain effect because of the rich blood supply to the tumor region. Meanwhile, TKIs could also induce vascular normalization and thus reduce hypoxia, increase intratumoral infiltration of cytotoxic T lymphocytes, and decrease regulatory T-lymphocyte recruitment, resulting in a more favorable immune microenvironment to enhance the antitumor activity of immunotherapy (21). Another recent case report found that CD8+ T cells may respond rapidly to pembrolizumab after exposure to lenvatinib, signifying that the CD8+ T cell sensitivity to immunotherapy was improved in the short term after treatment with TKIs (22). In all, antiangiogenic agents combined with immunotherapy can produce synergy effects.

Many indicators were reported to be used to predict the curative effect of immunotherapy, such as lactate dehydrogenase (LDH) (23), neutrophil-to-lymphocyte ratio (20), and neutrophil count (24, 25). But these indicators showed no relevance to the curative effect in our case. As for the patient, the baseline of eosinophil level was in the normal range and gradually increased during treatment (Figure 3A), suggesting that eosinophil may play an active role in the immune response. AFP may also be used as an indicator of response to the treatment because it was elevated before the treatment.

In summary, to the best of our knowledge, this is the first report of favorable response to the combination of antiangiogenic agents and immunotherapy in a PACC patient, which provides a new therapeutic approach for many tumors that have reached the treatment bottleneck or rare tumors that have no standard treatment.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

LQ and JS contributed equally. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by the National Natural Science Foundation of China (Nos. 81872484 and 82073365).

REFERENCES

1. Chaudhary P. Acinar Cell Carcinoma of the Pancreas: A Literature Review and Update. Indian J Surg (2015) 77(3):226–31. doi: 10.1007/s12262-014-1049-y
2. Al-Zaher N, Obeid A, Al-Salam S, Al-Kayyali BS. Acinic Cell Carcinoma of the Salivary Glands: A Literature Review. Hematol Oncol Stem Cell Ther (2009) 2(1):259–64. doi: 10.1016/j.hoe.2009.05.003
3. Luo Y, Hu G, Ma Y, Guo N, Li F. Acinar Cell Carcinoma of the Pancreas Presenting as Diffuse Pancreatic Enlargement: Two Case Reports and Literature Review. Med (Baltimore) (2017) 96(38):e7904. doi: 10.1097/MD.0000000000007904
4. Schmidt CM, Matos JM, Bentrem DJ, Talamonti MS, Lillemoe KD, Bilimoria KY. Acinar Cell Carcinoma of the Pancreas in the United States: Prognostic Factors and Comparison to Ductal Adenocarcinoma. J Gastrointest Surg (2008) 12(2):2078–86. doi: 10.1007/s11605-008-0705-6
5. Eriyuchi N, Aoyagi S, Hara M, Okuda K, Saito N, Fukuda S, et al. Large Acinar Cell Carcinoma of the Pancreas in a Patient With Elevated Serum AFP Level. Hepatobiliary Pancreat Dis Int (2000) 7(2):222–5. doi: 10.1007/s0053400050180
6. Hiraoka A, Nakahara H, Kawasaki H, Shimizu Y, Hidaka S, Imai Y, et al. Huge Pancreatic Acinar Cell Carcinoma With High Levels of AFP and Fucosylated AFP (AFP-L3). Intern Med (2012) 51(11):1341–9. doi: 10.21099/internmedicine.51.6536
7. Kitagami H, Kondo S, Hirano S, Kawakami H, Egawa S, Tanaka M. Acinar Cell Carcinoma of the Pancreas: Clinical Analysis of 115 Patients From Pancreatic Cancer Registry of Japan Pancreas Society. Pancreas (2007) 35(1):42–6. doi: 10.1097/mpa.0b013e31804bfdb3
8. Holen KD, Klimstra DS, Hummer A, Gonen M, Conlon K, Brennan M, et al. Clinical Characteristics and Outcomes From an Institutional Series of Acinar Cell Carcinoma of the Pancreas and Related Tumors. J Clin Oncol (2002) 20(24):4673–8. doi: 10.1200/JCO.2002.02.005
9. Cingolani N, Shaco-Levy R, Farruggio A, Klimstra DS, Rosai J. Alpha Fetoprotein Production by Pancreatic Tumors Exhibiting Acinar Cell Differentiation: Study of Five Cases, One Arising in a Mediastinal Teratoma. Hum Pathol (2000) 31(8):938–44. doi: 10.1016/s0046-8177(00)00975-9
10. Jornet D, Soyer P, Terris B, Hoeffel C, Oudjat A, Legmann P, et al. MR Imaging Features of Pancreatic Acinar Cell Carcinoma. Diagn Interv Imaging (2019) 100(7-8):427–35. doi: 10.1016/j.diii.2019.02.003
11. Agaimy A, Kaiser A, Becker K, Brasen JH, Wunsch PH, Adsay NV, et al. Pancreatic-Type Acinar Cell Carcinoma of the Liver: A Clinicopathologic Study of Four Patients. *Mod Pathol* (2011) 24(12):1620–6. doi: 10.1038/modpathol.2011.127

12. Seo S, Yoo C, Kim KP, Ryoo BY, Chang HM, Hong SM, et al. Clinical Outcomes of Patients With Resectable Pancreatic Acinar Cell Carcinoma. *J Dig Dis* (2017) 18(8):480–6. doi: 10.1111/1751-2980.12505

13. Lowery MA, Klimstra DS, Shia J, Yu KH, Allen PJ, Brennan MF, et al. Acinar Cell Carcinoma of the Pancreas: New Genetic and Treatment Insights Into a Rare Malignancy. *Oncologist* (2011) 16(12):1714–20. doi: 10.1634/theoncologist.2011-0231

14. Antoine M, Khitrik-Palchuk M, Saif MW. Long-Term Survival in a Patient With Acinar Cell Carcinoma of Pancreas. A Case Report and Review of Literature. *JOP* (2007) 8(6):783–9.

15. Kim CY, Lee SH, Jeon HM, Kim HK, Kang CM, Lee WJ. AFP-Producing Acinar Cell Carcinoma Treated by Pancreatectoduodenectomy in a Patient With a Previous Radical Subtotal Gastrectomy by Gastric Cancer. *Korean J Hepatobil Pancreat Surg* (2014) 18(1):33–7. doi: 10.14701/kjhbps.2014.18.1.33

16. Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, et al. Axitinib in Combination With Pembrolizumab in Patients With Advanced Renal Cell Cancer: A non-Randomised, Open-Label, Dose-Finding, and Dose-Expansion Phase 1b Trial. *Lancet Oncol* (2018) 19 (3):405–15. doi: 10.1016/S1470-2045(18)30081-0

17. Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, et al. Axitinib in Combination With Pembrolizumab in Patients With Either Treatment-Naive or Previously Treated Metastatic Renal Cell Carcinoma (Study 111/KEYNOTE-146): A Phase 1b/2 Study. *Lancet Oncol* (2021) 22(7):946–58. doi: 10.1016/S1470-2045(21)00241-2

18. Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, et al. Axitinib in Combination With Pembrolizumab in Patients With Either Treatment-Naive or Previously Treated Metastatic Renal Cell Carcinoma (Study 111/KEYNOTE-146): A Phase 1b/2 Study. *Lancet Oncol* (2021) 22(7):946–58. doi: 10.1016/S1470-2045(21)00241-2

19. Xue J, Zhang Y, Jia R, Yue C, Chang L, Liu R, et al. Anti-PD-1 Antibody SHR-1210 Combined With Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophageal Gastric Junction Cancer: An Open-Label, Dose Escalation and Expansion Study. *Clin Cancer Res* (2019) 25(12):315–23. doi: 10.1158/1078-0432.CCR-18-2484

20. Chen M, Yang S, Fan L, Wu L, Chen R, Chang J, et al. Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency But High Tumor Mutation Burden: A Case Report. *Pancreas* (2019) 48(9):1232–6. doi: 10.1097/MPA.0000000000013998

21. Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic Effect of Immune Checkpoint Blockade and Anti-Angiogenesis in Cancer Treatment. *Mol Cancer* (2019) 18(1):60. doi: 10.1186/s12943-019-0974-6

22. Shalata W, Iraqui M, Bhattacharya B, Fuchs V, Roisman LC, Cohen AY, et al. Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients With Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma). *Cancers (Basel)* (2021) 13(14):3630. doi: 10.3390/cancers13143630

23. Hernandez-Calvo A, Garcia-Alvarez A, Villacampa G, Ortiz C, Bodet D, Garcia-Patos V, et al. Dynamics of Clinical Biomarkers as Predictors of Immunotherapy Benefit in Metastatic Melanoma Patients. *Clin Transl Oncol* (2021) 23(2):311–7. doi: 10.1007/s12094-020-02420-9

24. Martens A, Wistuba-Hamprecht K, Geukes Foppen M, Yuan J, Postow MA, Wong P, et al. Baseline Peripheral Blood Biomarkers Associated With Clinical Outcome of Advanced Melanoma Patients Treated With Ipilimumab. *Clin Cancer Res* (2016) 22(12):2908–18. doi: 10.1158/1078-0432.CCR-15-2412

25. Donskov F. Immunomonitoring and Prognostic Relevance of Neutrophils in Clinical Trials. *Semin Cancer Biol* (2013) 23(3):200–7. doi: 10.1016/j.semcancer.2013.02.001

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2021 Qin, Shen, Yang and Zou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*